Last Price
5.40
Today's Change
-0.54 (9.09%)
Day's Change
5.35 - 6.47
Trading Volume
607,793
Overview
Market Cap
11 Million
Shares Outstanding
2 Million
Avg Volume
3,975,221
Avg Price (50 Days)
5.86
Avg Price (200 Days)
20.49
PE Ratio
-0.02
EPS
-326.40
Earnings Announcement
11-Nov-2024
Previous Close
5.94
Open
5.89
Day's Range
5.35 - 6.4739
Year Range
1.8 - 187.2
Trading Volume
607,891
Price Change Highlight
1 Day Change
-9.09%
5 Day Change
-10.30%
1 Month Change
140.00%
3 Month Change
-35.02%
6 Month Change
-63.41%
Ytd Change
-93.30%
1 Year Change
-96.37%
3 Year Change
-99.49%
5 Year Change
-99.49%
10 Year Change
-99.49%
Max Change
-99.49%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
2
CEO Morning Brief
Goldman Says Global Rate-cutting Cycle Bodes Well for US Dollar
3
CEO Morning Brief
Taylor Swift-backed Harris Puts Trump on Defensive in Fiery Debate
4
5
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
